Genelux Co. (NASDAQ:GNLX) VP Yong Yu Sells 10,400 Shares of Stock

Genelux Co. (NASDAQ:GNLX) VP Yong Yu sold 10,400 shares of Genelux stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $21.89, for a total value of $227,656.00. Following the completion of the transaction, the vice president now owns 106,135 shares of the company’s stock, valued at approximately $2,323,295.15. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Yong Yu also recently made the following trade(s):

• On Wednesday, September 13th, Yong Yu sold 29,800 shares of Genelux stock. The stock was sold at an average price of $21.14, for a total value of $629,972.00.
• On Wednesday, August 30th, Yong Yu sold 19,800 shares of Genelux stock. The stock was sold at an average price of $24.70, for a total value of $489,060.00.

Genelux Stock Up 12.3 %

Shares of NASDAQ GNLX opened at $25.38 on Tuesday. The business has a fifty day simple moving average of $24.55 and a two-hundred day simple moving average of $26.73. Genelux Co. has a twelve month low of $5.35 and a twelve month high of $40.98.

Genelux (NASDAQ:GNLX) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.09). As a group, sell-side analysts expect that Genelux Co. will post -0.94 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Maxim Group started coverage on Genelux in a research note on Tuesday, September 12th. They set a “buy” rating and a $40.00 price target for the company.

Institutional Trading of Genelux

Large investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System purchased a new stake in Genelux during the 2nd quarter valued at about $30,000. Tower Research Capital LLC TRC acquired a new position in shares of Genelux during the first quarter valued at approximately $32,000. American International Group Inc. purchased a new stake in shares of Genelux in the second quarter valued at approximately $44,000. JPMorgan Chase & Co. grew its position in shares of Genelux by 2,105.0% in the second quarter. JPMorgan Chase & Co. now owns 2,205 shares of the company’s stock valued at $72,000 after purchasing an additional 2,105 shares in the last quarter. Finally, Global Retirement Partners LLC purchased a new stake in shares of Genelux in the second quarter valued at approximately $82,000. Hedge funds and other institutional investors own 10.77% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer.